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ABSTRACT 
Background: Abnormal cholesterol metabolism changes the neuronal membrane and 
may promote amyloidogenesis. Oxysterols in cerebrospinal fluid (CSF) are related to 
Alzheimer's disease (AD) biomarkers in mild cognitive impairment and dementia. 
Cholesterol turnover is important for axonal and white matter (WM) microstructure 
maintenance.  
 
Objective: We aim to demonstrate that the association of oxysterols, AD biomarkers, 
and WM microstructure occurs early in asymptomatic individuals.  
 
Methods: We studied the association of inter-individual variability of CSF 24-
hydroxycholesterol (24-OHC), 27-hydroxycholesterol (27-OHC), 7-ketocholesterol (7-
KC), 7β-hydroxycholesterol (7β-OHC), amyloid-β42 (Aβ42), total-tau (t-tau), 
phosphorylated-tau (p-tau), neurofilament (NfL), and WM microstructure using 
diffusion tensor imaging, generalized linear models and moderation/mediation analyses 
in 153 healthy adults.  
 
Results: Higher 7-KC levels were related to lower Aβ42, indicative of greater AD 
pathology (p = 0.041) . Higher 7-KC levels were related to lower fractional anisotropy 
(FA) and higher mean (MD), axial (AxD), and radial (RD) diffusivity. 7-KC modulated 
the association between AxD and NfL in the corpus callosum splenium (B = 39.39, p = 
0.017), genu (B = 68.64, p = 0.000), and fornix (B = 10.97, p = 0.000). Lower Aβ42 
levels were associated to lower FA and higher MD, AxD, and RD in the fornix, corpus 
callosum, inferior longitudinal fasciculus, and hippocampus. The association between 
AxD and Aβ42 was moderated by 7K-C (p = 0.048).  
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Conclusion: This study adds clinical evidence to support the role of 7K-C on axonal 
integrity and the involvement of cholesterol metabolism in the Aβ42 generation process.  
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INTRODUCTION 
Oxysterols have been proposed as the link between brain cholesterol metabolism and 
Alzheimer’s disease (AD) 1. In AD, oxidative stress enhances the formation of 
oxysterols, which in turn increase pro-inflammatory mediator production and exacerbate 
neuronal damage, connecting all these processes in a vicious circle 2–4. Moreover, 
oxysterols play a fundamental role in APP-processing and β-amyloid1-42 (Aβ42) 
generation as they induce changes in cell membrane dynamics 5 that are related to the 
amyloidogenic processing in lipid rafts 6,7. While experimental work suggests that 
oxysterols contribute to amyloidogenesis 6–8, human studies have not shown an 
association between circulating oxysterols and CSF Aβ42 levels 9. Higher 24-
hydroxycholesterol (24OH-C) and 27-hidroxycholesterol (27OH-C), have been related 
to higher CSF total-tau (t-tau) and phosphorylated-tau (p-tau) levels in MCI and AD, 
but no in healthy people 10,11.  
To analyze the axolemma and myelin integrity, which are highly dependent on 
cholesterol metabolism and turnover, the assessment of white matter (WM) 
microstructure using DTI-MRI, is a valuable in vivo neuroimaging technique 12. Tensor-
derived measurements include fractional anisotropy (FA) and radial, mean, and axial 
diffusivities (RD, MD, AxD) 13. Despite the importance of cholesterol metabolism in 
the axolemma and myelin, few studies have analyzed the effect of cholesterol mis-
metabolism on the microstructure of WM 14–16, and to our knowledge there is no 
previous work investigating the effect of oxysterols on WM microstructure. It is well 
established that patients with AD or mild cognitive impairment (MCI) show lower FA 
and higher MD, AxD and RD values especially in areas related to cognition, such as the 
superior and inferior longitudinal fasciculus, hippocampus or corpus callosum 17,18. 
Moreover other studies have shown WM microstructure changes in cognitively healthy 
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people with positive amyloid biomarkers, especially in the fornix and the uncinate 
fascicle 19,20. 
To better understand the relationship between oxysterol homeostasis and neuronal 
integrity, we aimed to examine the association of CSF oxysterols, AD CSF biomarkers 
and WM microstructure, especially in regions associated to cognitive performance. For 
the present study we focus on the two major oxysterols synthetized enzymatically, 24-
hidroxycolesterol (24OH-C) and 27-hidroxycholesterol (27OH-C); and two synthetized 
non-enzymatically, 7β-hydroxycholesterol (7βOH-C) and 7-ketocholesterol (7K-C). We 
hypothesized that inter-individual variability of CSF oxysterols is related to changes in 
DTI indexes and is associated to lower Aβ42 and/or higher t-tau o p-tau levels. 
Furthermore, to investigate the role of inflammation and the occurrence of axonal 
damage, we have also looked at YKL-40 and neurofilament light (NfL). 
 
MATERIALS AND METHODS 
Subjects 
This study is a cross-sectional analysis of baseline data from the Gipuzkoa Alzheimer 
Project (GAP). The GAP study is an ongoing longitudinal study on preclinical and 
prodromal phases of AD. A cohort of 410 non-demented volunteers (aged 40-80) was 
recruited from the community through local media advertisements and presentations at 
the local Alzheimer Association. Baseline visits took place between June 2011 and 
January 2013. Exclusion criteria were dementia and any significant neurologic, 
systemic, or psychiatric disorder causing cognitive impairment. All participants 
completed a comprehensive clinical and neuropsychological evaluation, anthropometric 
and cardiovascular risk assessment, blood workup, apolipoprotein E (APOE) 
genotyping for the ε2/ε3/ε4 polymorphism, as well as brain magnetic resonance imaging 
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(MRI). Lumbar puncture for CSF biomarkers was optional. For the present study was 
selected GAP participants deemed clinically normal based on a global Clinical 
Dementia Rating (CDR) score of 0 21 with available CSF samples (n=153). For the 
white matter microstructure analyses, 26 participants were excluded due to incidental 
findings and/or present of MRI artifacts identified by visual inspection and noted non-
usable for this study.  
The study was approved by the local Ethics and Clinical Research Committee, and all 
subjects gave written informed consent to participate. 
Magnetic Resonance Imaging (MRI) 
Data acquisition 
Whole brain scans were obtained using a Siemens 3T Magnetom TrioTim scanner 
(Siemens, Erlangen, Germany) in combination with a 32-channel head coil. To increase 
the inter-subject homogeneity of the image acquisition, the AutoAlign Head LS 
software tool (Siemens) was used. Diffusion-weighted images were obtained using an 
echo planar imaging (EPI) sequence with the following specifications: TR 9300 ms, TE 
92 ms, voxel size: 1.7-mm isotropic, 71 consecutive slices, acquisition matrix 122×122 
(FOV 208 mm), 6/8 partial Fourier, 64 diffusion directions with b-value 1000 s/mm2, 
and one image with no diffusion weighting. The bandwidth was 1640 Hz/pixel. 
Image processing and analyses 
First, DICOM images were converted into 4D compressed NIfTI files and diffusion 
gradient directions were extracted with dcm2nii (part of MRIcron package, 
http://www.mccauslandcenter.sc.edu/mricro/mricron/). Then 4D brain volumes were 
processed and analysed by Tract-Based Spatial Statistics (TBSS), part of the FSL 
toolbox (FMRIB Software Library, Version 5.0.5; FMRIB, Oxford, United Kingdom) 
22–24. After image conversion, scalar DTI maps (FA, MD, AxD, and RD) were created 
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by fitting a tensor model to the raw diffusion data using FDT (FMRIB's Diffusion 
Toolbox). Then FA images were brain-extracted using Brain Extraction Tool (BET) 25, 
with b=0 as the reference volume. All subjects FA data were then aligned into a study-
specific FA template, using the nonlinear registration tool FNIRT 26, which uses a b-
spline representation of the registration warp field 27. The resulting warp-fields were 
then applied to MD, AxD and RD images. Due to the fact that in this study the subjects 
are middle to older age (40-77 years), we created a study-specific FA template instead 
of using the standard template (FMRIB58_FA) provided by FSL software, which is 
based on 58 subjects from 20 to 50 years. Before voxel-wise statistical analyses, all 
subject´s FA data were obtained and projected onto a mean FA tract skeleton, which 
represents the centres of all tracts common to the group 28. 
CSF biomarker measurements 
CSF was obtained and collected following international consensus recommendations as 
described previously 29. Samples were aliquoted and stored in polypropylene tubes at -
80ºC and shipped on dry ice to the Clinical Neurochemistry Laboratory in Gothenburg 
for analysis. Biomarker concentrations were measured by board-certified laboratory 
technicians using commercial assays as previously described30 (MSD: Aβ42 , Aβ40; 
Fujirebio Europe INNOTEST: t-tau and p-tau; R&D: YKL-40; and UmanDiagnostics: 
NfL). As provided by the laboratory participants with Aβ42/Aβ40 < 0.08 pg/mL, were 
considered amyloid positive (Aβ+). 
Quantification of CSF oxysterols by LC-MS/MS 
Human CSF samples (400 μl ) spiked with internal standards (1 ng 24-OHCd7, 0.25 ng 
25-OHCd6, 4 ng 27-OHCd6, 0.5 ng 7β-OHCd7, 15 ng 7-KCd7) was mixed with 1600 μl 
ice-cold methanol containing 4 mg/ml butyl hydroxytoluene (BHT) and incubated for 
10 min in ice. Samples were then centrifuged (14,000 xg at 4°C for 10 min) and the 
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methanolic supernatant was diluted with acidified water up to 12.5 % of 
methanol.  Oxysterol enrichment and quantification was performed as described by Dias 
et al 201831. Briefly, oxysterols were extracted using Oasis HLB Prime cartridges (bed 
wt. 30 mg, 1 ml, 96-well) and analysed by liquid chromatography UltiMate 3000 HPLC 
(Dionex, Thermo Scientific Ltd., Hemel Hempstead, UK) on-line coupled to the ESI-
QqLIT-MS/MS mass spectrometer (QTrap 5500, AB Sciex, Warrington, UK). Multiple 
reaction monitoring with transitions of 367.2/161 for 24-OHC, 367.4/ 147 for 25-OHC, 
385.4/161 for 27-OHC, 385.4/81 for 7β-OHC and 401.4/95 for 7-KC were used to 
collect data. Data were examined using Analyst Software 1.7.2 (AB Sciex, Warrington, 
UK).  
APOE genotype 
APOE genotype was determined using 1-stage polymerase chain reaction as previously 
described 32. Participants were classified as APOE ε4 carriers (APOE4+) if they had at 
least one ε4 allele, or as non-carriers (APOE4-).  
White matter hyperintensities 
Individual global white matter hyperintensity (WMH) was semiquantified by the 
Fazekas scale by an experienced neuroradiologist on fluid attenuation inversion 
recovery MRI sequences. Fazekas scale ranges between 0 and 3 (0= no WMH; 1 = 
focal/punctate lesions; 2 = beginning confluent lesions; 3 = confluent-diffuse lesions) 33. 
Statistical Analysis 
To assess the appropriateness of parametric statistics, the Kolmogorov-Smirnov test was 
used to examine the normality of oxysterol distribution. Frequency distributions were 
calculated for categorical variables, and means (standard deviations) or median 
(percentile25-percentile75) were calculated for continuous variables. 
Oxysterols and AD biomarkers 
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Separate generalized linear models (GLM) were conducted to explore the association 
between oxysterol measured by 24OH-C, 27OH-C, 7K-C, 7βOH-C and CSF biomarkers 
(Aβ42, t-tau, p-tau) adjusted by age, sex and APOE genotype. If a significant association 
was found, we examined the role of YKL40 including this variable in a new regression 
model.  
White matter microstructure 
All DTI indexes, were correlated with age, sex and WMH, therefore all analysis were 
adjusted for these confounders. To test the association between oxysterols and WM 
microstructure as indexed by the DTI measurements (FA, MD, RD, AxD), whole-brain 
voxel-wise statistical analyses were performed with a nonparametric permutation 
inference tool (randomise, part of the FSL toolbox). For these analyses 5000 
permutations were generated and Threshold-Free Cluster Enhancement (TFCE) was 
conducted as a thresholding option 34. All the resulting statistical maps were corrected 
for multiple comparisons with family wise error (FWE), thresholded at p<0.05 and only 
clusters with at least 100 contiguous voxels were defined as significant clusters. 
Resulting significant clusters were labelled using the atlas available through FSL 
toolbox (ICBM-DTI-81 white matter labels atlas). 
Based on previous results linking WM microstructure with cognitive performance 17,35, 
special attention was focused on the following regions: corpus callosum, inferior and 
superior longitudinal fasciculus, cingulate gyrus, hippocampus, uncinate fasciculus, 
fornix (column+body) and fornix cres/stria terminalis These regions were labelled using 
the atlas available through FSL toolbox (ICBM-DTI-81 white matter labels atlas).  
If an oxysterol showed a significant association with an AD biomarker and a DTI index, 
the effect of the biomarker on the DTI index was analysed in the voxels where the 
oxysterol had shown a significant effect. Individual mean values for DTI indexes were 
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extracted in regional clusters that were significantly associated with oxysterols 
according to TBSS analysis (FEW-corrected p<0.05). For these analyses, GLMs were 
conducted. The dependent variable was the mean of the DTI measures of each region 
and the predictor was the biomarker. The DTI indexes were multiplied by 1000 in the 
analyses 36.  
To better understand the association between oxysterols, biomarkers and WM 
microstructure in areas related to cognition, GLMs were designed for the DTI indexes 
obtained from each region where the oxysterol and biomarkers showed a significant 
effect. The biomarker was the dependent variable and oxysterol, DTI index and the 
interaction between both were predictive variables. Mediation and moderation analyses 
were performed to better understand the associations found between oxysterols, AD 
biomarkers and cognitive regions WM microstructure. Moderation is shown up by a 
significant interaction effect. 
Finally, we conducted new GLMs to study the effect of the interaction between 
oxysterols and DTI indexes and between biomarkers and DTI indexes on CSF NfL 
levels, as a biomarker of axonal damage. Mediation and moderation analyses were 
performed to better understand the associations found between oxysterols, AD 
biomarkers, cognitive regions DTI indexes and NfL. All models were controlled by sex, 
age, WMH and APOE genotype. 
Statistical analyses were conducted in SPSS version 20. For mediation and moderation 
analysis we applied the PROCESS macro for SPSS (version 3) by Andrew F.Hayes 
(http://www.afhayes.com). 
RESULTS 
Descriptive data for the whole sample (n = 153, CDR score= 0) are shown in Table 1. 
Participant age range was 40-75, 67 (43.8%) were women and mean MMSE score was 
29.  
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Oxysterols and CSF biomarkers for AD pathology  
To study the association between oxysterol levels and CSF AD biomarkers, GLMs were 
conducted among 153 healthy participants controlling for age, gender and APOE 
genotype. 7K-C was associated with Aβ42 (B = -0.20; p = 0.041) (Table 2). There were 
no effects of 7K-C on t-tau or p-tau. The other oxysterols, 24OH-C, 27OH-C, 7βOH-C, 
did not show any significant effect on any CSF biomarker. 
As Aβ42 was significantly correlated with YKL40 (rs = 0.244; p = 0.003) and 7K-C is 
related to apoptosis and inflammation 37 we introduced YKL40 in the model. YKL40 (B 
= 0.001; p = 0.000) and 7K-C (B= -0.19; p = 0.044) showed a significant effect on Aβ42. 
. The interaction between YKL40 and 7K-C, was not significant (B= -5.88E-7; p = 
0.812).  
Oxysterols and white matter microstructure 
To study the correlation between oxysterols and WM microstructure, voxel-wise 
correlational analysis was conducted among 127 healthy participants controlling for 
age, gender and white matter hyperintensities. Descriptive data for the subsample with 
available MRI included significantly more women than the all sample (p = 0.005) 
(Table 1). 
TBSS analysis detected a significant negative association between 7K-C and FA (Figure 
1A). Most of these voxels were located in the corpus callosum. Significant associations 
were also seen in the following regions: left anterior and right posterior corona radiata, 
left external capsule, right hippocampus and right superior longitudinal fascicule. We 
did not observe significant positive association between 7K-C and FA. Analyses also 
revealed a significant positive association correlation between 7K-C and MD (Figure 
1B), AxD (Figure 1C) and RD (Figure 1D) distributed throughout the whole brain WM 
in both hemispheres. We did not observe significant negative association between 7K-C 
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and MD, AxD or RD. Table 3 shows the distribution and proportion of voxels where a 
significant association between 7K-C and each DTI measure was detected in every 
cognitive region. 
There was no significant effect for 24OH-C, 27OH-C and 7βOH-C in any of the DTI 
measurements. 
Oxysterols, CSF biomarkers for AD pathology and cognitive regions white matter 
microstructure 
As 7K-C had a significant effect on Aβ42, the association between Aβ42 and DTI indexes 
of WM microstructure was analysed in the voxels where 7K-C showed a significant 
effect on each index (Table 3). GLMs were adjusted for age, gender, WMH and APOE 
genotype.   
Aβ42 had a positive effect on FA of the splenium of the corpus callosum and AxD of 
right hippocampus, and a negative effect on the MD of the body of the corpus callosum, 
fornix (column+body) and left inferior longitudinal fasciculus; on AxD of the genu and 
splenium of the corpus callosum and fornix (Column+body); and on RD of the fornix 
(column+body) (Figure 2). The βA+ group (n=25) had significantly higher MD, AxD 
and RD values in the fornix (column+body) than βA- group (n=126) (MD: βA+, median 
= 1.75; βA-, median = 1.42; p = 0.001 / AxD: βA+, median = 2.32; βA-, median = 2.03; 
p = 0.003 / RD: βA+, median = 1.50; βA-, median = 1.11; p = 0.002) (Figure 2). 
To explore the association between 7K-C, Aβ42 and WM microstructure, the effect of 
7K-C and its interaction with the WM microstructure indexes (FA*7K-C; MD*7K-C; 
AxD*7K-C; RD*7K-C) on the level of Aβ42 was studied in the areas related to 
cognitive performance where the 7K-C and Aβ42 showed significant effect. Higher MD, 
AxD and RD of the fornix, and higher AxD of the splenium and genu of the corpus 
callosum, right hippocampus and left inferior longitudinal fasciculus were related to 
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lower Aβ42 (Table 4). In these model 7K-C and the interactions between 7K-C and DTI 
measures were not significant. In the left inferior longitudinal fasciculus model, AxD, 
7K-C and 7K-C*AxD interaction showed a significant effect. Moderation analyses 
showed that the relationship between AxD and Aβ42 was moderated by 7K-C level (B = 
3.87, p = 0.048). When YKL40 was included in the analyses, the moderation effect of 
7K-C was not significant (p = 0.082).  
Oxysterols, CSF AD biomarkers, axial diffusivity and neurofilament,  
As AxD is related to axonal damage, the effect of the 7K-C*AxD interaction, and the 
Aβ42*AxD interaction on NfL for areas related to cognition where 7K-C and Aβ42 had 
significant effect were analyzed in separate GLMs. The 7K-C*AxD interaction showed 
a significant effect on NfL in the fornix and in the splenium and genu of the corpus 
callosum (Table 5). In these regions, the relationship between AxD and NfL was 
moderated by 7K-C (Fornix: B = 1.53, p = 0.000; splenium: B = 5.51, p = 0.017; Genu: 
B = 9.61, p = 0.000). The Aβ42*AxD showed no significant effect on NfL in any region. 
 
DISCUSSION 
We have investigated the association between oxysterols, CSF AD biomarkers and WM 
microstructure in cognitive regions in a population of cognitively healthy middle-aged 
subjects. To our knowledge, this might be the first study on the effect of oxysterols on 
WM microstructure and the first to report that higher 7K-C levels are related to lower 
Aβ42. 7K-C had a negative effect on FA and a positive effect on MD, AxD and RD in 
multiple cognitive regions. Moreover, 7K-C modulated the association between AxD 
and axonal loss, as measured by NfL, in the splenium and genu of the corpus callosum 
and fornix. Interestingly, in the voxels where 7K-C showed a significant effect on FA, 
MD, AxD and RD, Aβ42 also  showed positive association with FA and negative effects 
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on MD, AxD and RD in the fornix, corpus callosum, inferior longitudinal fasciculus and 
hippocampus. Furthermore subjects who were βA+ had significantly higher MD, AxD 
and RD values in the fornix than the βA- group.  
Previous case-control studies on CSF oxysterol levels have reported that 24OH-C and 
27OH-C levels are higher in patients with AD or MCI 10,11,38. Other studies, analyzing 
patients with AD or MCI and controls al together, have shown positive correlations 
between 24OH-C CSF concentrations and t-tau and p-tau levels, but not with Aβ42 10,39. 
However these correlations were significant only in the AD or MCI group, and no in 
healthy people. Popp and colleagues described a positive correlation between 24OH-C 
and sAPPα and sAPPβ in patients with AD, but no with Aβ42 40. Our results confirm the 
absence of association between 24OH-C and 27OH-C and CSF AD biomarkers in 
cognitively healthy adults. This suggests that if 24OH-C and 27OH-C are involved in 
AD pathophysiology this would not represent an early event. Although 24-OHC and 27-
OHC are the oxysterols most widely considered to be potentially implicated in AD 
pathogenesis, the possible involvement of oxysterols resulting from cholesterol 
autoxidation is now emerging. In fact, in a recent systematic analysis of oxysterols in 
post-mortem human AD brains, the level of some of the oxysterols deriving from 
cholesterol autoxidation were higher in subjects in the Braak I-II stages than in controls, 
and there were no differences in the levels of the two oxysterols of enzymatic origin 41. 
7K-C is a major product of reactive oxygen species (ROS)-caused oxidation of 
cholesterol 42. We found that higher 7K-C levels were associated with lower Aβ42. This 
result is in line with previous model lipid membrane studies reporting a relation 
between 7K-C and Aβ42 43,44. In the study by Kim and colleagues, they observed that 
partial substitution of cholesterol with 7K-C in the model lipid membrane enhances 
Aβ42 insertion into the lipid bilayer, by decreasing intramolecular cohesive interactions  
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44. In the same line, Phan and colleagues demonstrated that 7K-C renders lipid bilayer 
less condensed and more fluid than cholesterol, thus accelerating Aβ42 association with 
the bilayer 6, specially the protofibrillar Aβ42 43. Moreover, a recent model lipid 
membrane study demonstrated that cholesterol and 7K-C have different effects on 
membrane-mediated aggregation of Aβ42. While cholesterol inhibited the nucleation 
step and accelerated fibrillar Aβ42 growth, the partial substitution of membrane 
cholesterol with 7K-C slightly increased the nucleation fase and remarkably decreased 
fibril elongation 45. The oligomers or protofibrillar Aβ42 formed in the nucleation step 
are reportedly more toxic than soluble monomers and mature fibrils 46. These papers 
suggested that cholesterol and 7K-C can modulate interaction of Aβ42 with cell 
membranes by influencing the fibrillation of the peptide. Our work adds clinical 
evidence to support these experimental studies on the relation between 7K-C and Aβ42. 
An in vitro study showed  that 7K-C induced apoptosis in cells associated with 
increased ROS generation, ER stress and upregulated caspase-3/7 activity 37. Thus, we 
hypothesized that neuroinflammation, as measured by YKL40 had an effect in the 
relation between 7K-C and Aβ42. Our results demonstrated that both, 7K-C and YKL40, 
have a significant effect on Aβ42, but there is no interaction between 7K-C and YKL40, 
suggesting that both influence the amyloidogenic process by different pathways.  
Regarding WM microstructure, to our knowledge, this might be the first study 
investigating the effect of oxysterols on WM microstructure. We found that 7K-C had a 
negative effect on FA and a positive effect on MD, AxD and RD in multiple cognitive 
regions. Moreover, 7K-C modulates the relation between NfL, a marker of axonal 
damage 47, and AxD, the DTI index related to axonal damage 48. 7K-C induces 
oxidative stress 37 which in turn induces activation of microglia and astrocytes with a 
consequent increase of pro-inflammatory mediator production and exacerbating 
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neuronal damage 2. Our results suggest that the WM microstructure changes related to 
neuronal and axonal damage are related to altered cholesterol metabolism and increased 
membrane levels of 7K-C. With respect to Aβ42, we found a relation between lower 
CSF Aβ42 and lower FA and higher MD, AxD or RD in areas related to cognitive 
performance such as fornix, corpus callosum, inferior longitudinal fasciculus and 
hippocampus in those voxels where 7K-C showed a significant effect on the DTI 
indexes. Previous studies have shown lower FA and higher MD in patients with AD, 
especially in areas such as corpus callosum, fornix, superior and inferior longitudinal 
fasciculus or cingulum 17,18,49. Similar changes in WM microstructure are also found in 
cognitively healthy persons with abnormal Aβ42 levels, specially in the uncinate 
fasciculus and fornix 19,20. These findings are in line with our results. In our study βA+ 
subjects have significantly higher MD, AxD and RD values in the fornix than the βA- 
group.  
We have found a relation between Aβ42, 7K-C and WM microstructure in cognitive 
regions. Axon integrity depends mainly on the axolemma structure which in turn 
depends on cholesterol turnover. Our work would suggest that cholesterol metabolism 
and integration of 7K-C in the axolemma could change the structure of the membrane, 
alter WM microstructure and modulate the amyloidogenic process. 
The GAP study has allowed us to analyze a rigorously phenotyped cohort with strict 
clinical and cognitive criteria to exclude participants with cognitive impairment 
rigorously. However, the study must also be interpreted in the light of its limitations. 
The principal one is that DTI metrics are an indirect measure of WM microstructure and 
the influence of crossing fibers makes the interpretation more complicated in all DTI 
studies. However, the strength of the study is that participants performed a high 
resolution 3T-DWI with 65 directions which has allowed to realize robust estimates of 
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tensor derived-properties 50. This is a cross-sectional study, which cannot characterize 
how the association between 7K-C, Aβ42 and WM microstructure changes over time. 
Longitudinal follow-up data on the GAP study cohort are now being collected and will 
be the subject of further analysis to confirm these cross-sectional findings. 
In conclusion, this study shows that interindividual variability of CSF 7K-C levels in 
healthy adults are associated with Aβ42 levels and WM integrity in cognitive regions. 
Perhaps, for the first time, this study adds clinical evidence to support experimental 
studies on the potential effect of 7K-C in the Aβ42 aggregation process and membrane 
structure. Furthermore, this study reports, possibly for the first time, the effect of 7K-C 
on the WM microstructure and its modulating effect on the relation between axonal 
damage and white matter microstructure, suggesting that WM microstructure changes 
related to 7K-C could be a mirror of the neuronal damage induced by 7K-C. 
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Figure legends 
Figure 1: Association between 7K-C and white matter microstructure. Data adjusted for 
age, sex and white matter hyperintensities (family-wise error-corrected, thresholded at 
p<0.05, n=127). Results are shown as an overlay on the FSL standard T1 template brain 
(coordinates according to MINI152 template). Abbreviations: 7K-C, 7-ketocholesterol; 
L, left; R, right, FA, fractional anisotropy; MD, mean diffusivity; AxD, axial diffusivity; 
RD, radial diffusivity. 
Figure 2: Association between Aβ42 and white matter microstructure. Note: analyses 
were performed in the voxels were 7-ketocholesterol showed significant effect. 
Adjusted for age, sex, white matter hyperintensities and APOE genotype. Abbreviations: 
Aβ42, β-amyloid1-42; FA, fractional anisotropy; MD, mean diffusivity; AxD, axial 
diffusivity; RD, radial diffusivity. 
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Tables 
Table 1: Sample characteristics 
 
Note. Significant effects are shown in bold. Mean (Standard Deviation) of measures, median (p25-p75) and 
in categorical variables, n (%). 24OH-C, 24-hidroxycholesterol; 27OH-C, 27-hidroxycholesterol; 7K-C, 7-
ketocholesterol; 7βOH-C, 7β-hidroxycholesterol; MMSE, Mini Mental Status Examination; APOE, 
Apolipoprotein E; NfL, Neurofilament Light 
a. Comparison between participants with and without MRI. 
  
Characteristic All sample (n=153) Sample with MRI (n=127) pa 
Age, years  57.09 (53.06 – 62.12) 56.85 (53.01-62.35) 0.664 
Sex (% female) 67 (43.8) 78 (61.4) 0.005 
Education, years 14 (11 – 17) 14.00 (11-17) 0.525 
MMSE, score 29 (28 – 30) 29.00 (28-30) 0.719 
APOE ε4 carrier 36 (23.5) 27 (21.3) 0.202 
Fazekas scale, n (%)   0.953 
0 86 (56.6) 71 (55.9)  
1 52 (34.2) 44 (34.6)  
2 9 (5.9) 8 (6.3)  
3 5 (3.3) 4 (3.1)  
24OH-C, ng/dl 12.47 (9.70-19.05) 12.38 (9.70-19.06) 0.973 
27OH-C, ng/ml 2.28 (1.24) 2.29 (1.10) 0.924 
7K-C, ng/dl 97.18 (45.99-174.66) 93.71 (45.40-146.12) 0.066 
7βOH-C, ng/dl 19.46 (12.85-33.88) 19.65 (12.85-34.54) 0.915 
Aβ42, pg/ml 478.73 (152.22) 478.31 (154.02) 0.939 
t-tau, pg/ml 268.40 (201.87-336.76) 270.87 (194.24-353.65) 0.451 
p-tau, pg/ml 38.50 (30-46) 39.00 (30-47) 0.678 
YKL40, pg/ml  121759.67 (92656.61-153900.96) 119796.16 (88460.09-153787.68) 0.536 
NfL, pg/ml 
501.86 (397.22-630.78) 
501.86 (391.12-630.78) 0.730 
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Table 2: Relationship between CSF oxysterols and AD CSF biomarkers 
Note. Significant effects are shown in bold. B, beta coefficient; CI, confidence interval; APOE4+ = apolipoprotein E 
ε4 carrier, APOE4- = apolipoprotein E ε4 non-carrier; 24OH-C, 24-hidroxycholesterol; 27OH-C, 27-
hidroxycholesterol; 7K-C, 7-ketocholesterol; 7βOH-C, 7β-hydroxycholesterol; Aβ42 = β-amyloid1-42; t-tau = total-tau; 
p-tau = phosphorylated tau 
 
a. Set to zero because this parameter is redundant. 
  
 Aβ42  t-tau  p-tau 
B (95%IC) p  B (95%IC) p  B (95%IC) p 
Model 1         
24OH-C -0.91 (-3.31-1.49) 0.457  -0.19 (-1.82-1.45) 0.821  0.01 (-0.19-0.21) 0.939 
Age 1.35 (-2.23-4.92) 0.460  6.76 (4.33-9.19) 0.000  0.77 (0.48-1.07) 0.000 
Gender: F -4.39 (-52.61-43.84) 0.858  -7.42 (-40.26-25.42) 0.658  0.08 (-3.89-4.06) 0.967 
Gender: M 0a   0a   0a  
APOE4+ -52.10 (-108.91-4.70) 0.072  21.37 (-17.14-59.88) 0.277  2.58 (-2.07-7.23) 0.277 
APOE4- 0a   0a   0a  
Model 2         
27OH-C 5.86 (-13.85-25.57) 0.560  1.98 (-11.43-15.39) 0.772  0.91 (-0.70-2.53) 0.266 
Age 1.31 (-2.29-4.90) 0.476  6.78 (4.34-9.22) 0.000  0.80 (0.50-1.09) 0.000 
Gender: F -5.68 (-54.74-43.38) 0.820  -6.52 (-39.89-26.84) 0.702  0.06 (-3.96-4.09) 0.975 
Gender: M 0a   0a   0a  
APOE4+ -54.15 (-112.04-3.74) 0.067  23.42 (-15.78-62.63) 0.242  2.82 (-1.89-7.54) 0.241 
APOE4- 0a   0a   0a  
Model 3         
7K-C -0.20 (-0.39--0.01) 0.041  -0.06 (-0.19-0.07) 0.338  -0.01 (-0.03-0.00) 0.170 
Age 1.44 (-2.08-4.96) 0.422  6.79 (4.38-9.20) 0.000  0.79 (0.50-1.08) 0.000 
Gender: F -3.17 (-51.10-44.76) 0.897  -6.33 (-39.23-26.57) 0.706  0.17 (-3.80-4.14) 0.934 
Gender: M 0a   0a   0a  
APOE4+ -54.87 (-111.25-1.51) 0.056  19.96 (-18.58-58.51) 0.310  2.42 (-2.23-7.06) 0.308 
APOE4- 0a   0a   0a  
Model 4         
7β-C 0.44 (-0.43-1.32) 0.321  -0.42 (-1.00-0.16) 0.160  -0.05 (-0.12-0.02) 0.201 
Age 0.91 (-2.68-4.49) 0.619  6.86 (4.44-9.29) 0.000  0.79 (0.49-1.08) 0.000 
Gender: F -6.39 (-55.54-42.76) 0.799  -9.26 (-42.55-24.04) 0.586  -0.18 (-4.21-3.85) 0.930 
Gender: M 0a   0a   0a  
APOE4+ -55.91 (-113.10-1.29) 0.055  23.15 (-15.44-61.75) 0.240  2.75 (-1.91-7.41) 0.248 
APOE4- 0a   0a   0a  
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Table 3. Distribution and proportion of significant voxels for the association between 
7K-C and cognitive regions DTI indexes. 
Region (Nº of voxels)a Number of significant voxels (%)b  
FA MD AxD RD 
CC Genu (8851) 429 (4.85) 470 (5.31) 98 (1.11) 2 (0.02) 
Body (13711)  247 (1.80) 658 (4.80) 0 21 (0.15) 
Splenium (12729)  223 (1.75) 524 (4.12) 116 (0.91) 387 (3.04) 
Fornix Column+body (659)  0 50 (7.59) 53 (8.04) 47 (7.13) 
Cres/stria terminalis Right (1124)  0 36 (3.20) 16 (1.42) 42 (3.74) 
Cres/stria terminalis Left (1125)  0 68 (6.04) 55 (4.89) 61 (5.42) 
ILF Right (2228)  0 298 (13.38) 231 (10.37) 255 (11.45) 
Left (2231)  0 258 (11.56) 240 (10.76) 35 (1.57) 
SLF Right (6607)  118 (1.79) 578 (8.75) 332 (5.02) 617(9.34) 
Left (6605)  0 447 (6.77) 4 (0.06) 397 (6.01) 
GC Right (2342)  0 31 (1.32) 0 0 
Left (2751)  16 (0.58) 42 (1.53) 0 0 
Hippoc. Right (1236)  239 (19.34) 229 (18.53) 28 (2.27) 247 (19.98) 
Left (1155)  0 120 (10.39) 0 0 
FU Right (380)  0 38 (10.00) 0 0 
Left (376)  0 0 0 0 
Note. Number of significant voxels (FEW-corrected and p<0.05). CC, corpus callosum; ILF, inferior longitudinal 
fasciculus; SLF, superior longitudinal fasciculus; GC, gyrus cingulum; Hippoc., hippocampus; UF, uncinated fasciculus  
a. In parenthesis, the number of voxels according to ICBM-DTI-81 white matter labels atlas 
b. In parenthesis the proportion of significant voxels with respect to the total number of voxels in this area 
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Table 4: Effect of 7K-C and cognitive regions WM microstructure on Aβ42 levels. 
Note. Significant effects are shown in bold. B, beta coefficient; CI, confidence interval; Aβ42 = .β-amyloid1-42; CC-S, corpus 
callosum-splenium; CC-B, corpus callosum-body; CC-G, corpus-callosum-genu; ILF L, inferior longitudinal fasciculus left; 
FRNX, fornix (column+body); Hippoc. R, hippocampus right, FA, fractional anisotropy; MD, mean diffusivity; AxD, axial 
diffusivity; RD, radial diffusivity. 
a. Generalized linear models adjusted for gender, age, white matter hyperintensities and APOE 
genotype 
  
 FRNX (MD)  FRNX (AxD)  FRNX (RD) 
B (95%IC) pa  B (95%IC) pa  B (95%IC) pa 
7K-C -0.15 (-0.76-0.46) 0.635  -0.13 (-0.98-0.72) 0.771  -0.15 (-0.65-0.36) 0.575 
MD -121.19 (-207.72-34.66) 0.006       
7K-C*MD 0.02 (-0.29-0.34) 0.890       
AxD    -131.74 (-230.42-33.06) 0.009    
7K-C*AxD    0.01 (-0.34-0.36) 0.955    
RD       -112.62 (-192.35-32.89) 0.006 
7K-C*RD       0.02 (-0.28-0.32) 0.884 
 CC-S (FA)  CC-S (AxD)  CC-B (MD) 
B (95%IC) pa  B (95%IC) pa  B (95%IC) pa 
7K-C 0.65 (-4.96-6.26) 0.820  -2.50 (-6.14-1.13) 0.177  0.80 (-2.61-4.21) 0.645 
FA 1.09 (-0.39-2.57) 0.148       
7K-C*FA -0.001 (-0.008-0.006) 0.796       
AxD    -472.22 (-900.19-44.26) 0.031    
7K-C*AxD    1.54 (-0.80-3.89) 0.198    
MD       -457.53 (-1498.56-583.51) 0.389 
7K-C*MD       -1.198 (-5.651-3.254) 0.598 
 CC-G (AxD)  ILF L (AxD)  Hippoc. R (AxD) 
B (95%IC) pa  B (95%IC) pa  B (95%IC) pa 
7K-C -0.31 (-4.16-3.54) 0.873  -5.42 (-10.49-0.35) 0.036  -0.02 (-1.17-1.13) 0.976 
AD -440.17 (-813.01-67.33) 0.021  -722.00 (-1287.77-156.23) 0.012  248.42 (57.91-438.94) 0.011 
7K-C*AxD 0.13 (-2.30-2.56) 0.914  3.87 (0.17-7.58) 0.040  -0.23 (-1.35-0.89) 0.686 
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Table 5: Effect of 7K-C, Aβ42 and cognitive regions axial diffusivity on NfL levels. 
Note. Significant effects are shown in bold. B, beta coefficient; CI, confidence interval; Aβ42 = β-
amyloid1-42; CC-S, corpus callosum-splenium; CC-G, corpus-callosum-genu; ILF L, inferior 
longitudinal fasciculus left; FRNX, fornix (column+body); Hippoc. R, hippocampus right, AxD, axial 
diffusivity; NfL, neurofilament light; 7K-C, 7-ketocholesterol. 
b. Generalized linear models adjusted for gender, age, white matter hyperintensities and  APOE 
genotype 
 
 
 FRNX   CC-S  
B (95%IC) pa  B (95%IC) pa 
Model 1      
AxD -3.37 (-4.88--1.86) 0.000  -633.11 (-1425.09-158.87) 0.117 
7K-C -202.83 (-377.69--27.97) 0.023  -8.19 (-14.91--1.46) 0.017 
AxD *7K-C 1.54 (0.92-2.15) 0.000  5.52 (1.17-9.86) 0.013 
Model 2      
AxD 331.43 (-121.02-783.88) 0.151  -456.89 (-2281.61-1367.83) 0.624 
Aβ42 1.17 (-0.84-3.18) 0.254  -2.13 (-7.69-3.43) 0.452 
AxD*Aβ1-42 -0.42 (-1.36-0.53) 0.388  1.60 (-2.16-5.37) 0.404 
 CC-G   ILF L  
B (95%IC) pa  B (95%IC) pa 
Model 1      
AxD -855.54 (-1523.47--187.60) 0.012  -447.54 (-1515.27-620.18) 0.411 
7K-C -14.87 (-21.77--7.97) 0.000  2.84 (-6.72-12.41) 0.561 
AxD *7K-C 9.61 (5.26-13.96) 0.000  -1.75 (-8.73-5.24) 0.624 
Model 2      
AxD -216.69 (-1753.82-1320.44) 0.782  1016.47 (-1347.23-3380.17) 0.399 
Aβ42 -1.28 (-5.60-3.05) 0.563  3.79 (-2.51-10.10) 0.238 
AxD*Aβ42 1.01 (-1.85-3.86) 0.490  -2.75 (-7.55-2.05) 0.261 
 Hippoc. R    
B (95%IC) pa    
Model 1      
AxD -45.98 (-413.78-321.81) 0.806    
7K-C 0.69 (-1.54-2.91) 0.546    
AxD *7K-C -0.30 (-2.46-1.86) 0.785    
Model 2      
AxD -19.19 (-962.30-923.92) 0.968    
Aβ42 0.27 (-1.42-1.97) 0.750    
AxD*Aβ42 -0.07 (-1.89-1.76) 0.942    
